This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Synageva BioPharma™ Reports Third Quarter 2013 Financial Results

Stocks in this article: GEVA

Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today reported third quarter 2013 financial results and provided other business updates.

Synageva announces the hiring of Gregory A. Grabowski, M.D., FACMG

Gregory A. Grabowski, M.D. joins Synageva as a distinguished physician and accomplished researcher in the field of rare, genetic diseases. In his role at Synageva, Dr. Grabowski will assist in evaluating, designing, and implementing strategies to advance Synageva’s earlier stage pipeline programs.

“I am delighted to join Synageva at this exciting stage of the company’s evolution,” said Dr. Grabowski. “Joining Synageva represents a significant opportunity for me to support the company’s goals for patients with rare diseases and to extend my life’s dedication to developing life-changing therapies for patients suffering from these devastating diseases.”

“Dr. Grabowski is a leading authority in genetic and lysosomal storage diseases, including Gaucher and Fabry disease, and was an early pioneer in understanding LAL Deficiency,” said Anthony Quinn, MBChB, Ph.D., FRCP, Senior Vice President and Chief Medical Officer and Head of R&D of Synageva. “On behalf of the company, I welcome Greg to our team. We look forward to his contribution that will help us deliver on our commitment to advancing our pipeline programs and making a meaningful impact on the lives of patients.”

Prior to joining Synageva, Dr. Grabowski was most recently Director of the Division of Human Genetics at the Cincinnati Children’s Hospital Research Foundation and Professor of Molecular Genetics, Biochemistry, and Pediatrics at the University of Cincinnati College of Medicine, Cincinnati, Ohio. He has authored more than 290 scientific publications and is a regular reviewer of 10 different medical journals. In addition to his extensive clinical experience, Dr. Grabowski’s research interests include lysosomal storage diseases and enzyme replacement therapies. His research, particularly in lysosomal storage diseases, has been funded by the National Institutes of Health for the past 25 years. Dr. Grabowski received his B.A. from the University of Minnesota and his M.D. from the University of Minnesota Medical School.

1 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs